Learn how the virus works and the multiple ways that Oligonucleotide therapies can stop it. After 30+ years of research and development, these therapies are starting to help treat a wide range of diseases, and they provide new approaches to vaccines to teach our immune system how to defend itself against new viruses that have never before infected humans, and which hide from the immune system – the coronavirus SARS-CoV-2 does this very well, and we should expect in the future more pandemics of other viruses. Join us to learn how the Moderna and related new vaccines and treatments can get us past this and future pandemics.
Arthur M. Krieg, MD has worked in the oligonucleotide field since the 1980s. In 2004 he co-founded The Oligonucleotide Therapeutics Society, a non-profit international group of scientists dedicated to developing drugs from RNA and DNA technologies. He trained in immunology/rheumatology at the NIH and then joined the University of Iowa, becoming Professor of Internal Medicine. Art discovered immune stimulatory CpG DNA in 1994, which led to a new approach to immunotherapy and vaccine adjuvants. Based on this technology he co-founded a biotech company, Coley Pharmaceutical Group in 1997, discovering and taking 4 novel immune activating oligonucleotides into clinical development. Coley was acquired by Pfizer in 2008, and Art subsequently continued to lead research and development of new oligonucleotide drugs at Pfizer and other companies, most recently founding Checkmate Pharmaceuticals in 2015 to develop immune activating CpG oligonucleotides for cancer immunotherapy. He serves on the scientific advisory boards of several companies involved in oligonucleotide therapeutics and since 2017 is a Professor in the University of Massachusetts RNA Therapeutics Institute.
